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Abstract: 
Mast cells (MC) are potent innate immune cells that accumulate in chronically inflamed tissues. 
MC express the IL-33 receptor IL-1 receptor-related protein ST2 at high level, and this IL-1 
family cytokine both activates MC directly and primes them to respond to other proinflammatory 
signals. Whether IL-33 and ST2 play a role in MC survival remains to be defined. In skin-
derived human MC, we found that IL-33 attenuated MC apoptosis without altering proliferation, 
an effect mediated principally through the antiapoptotic molecule B-cell lymphoma-X large 
(BCLXL). Murine MC demonstrated a similar mechanism, dependent entirely on ST2. In line 
with these observations, St2−/− mice exhibited reduced numbers of tissue MC in inflamed 
arthritic joints, in helminth-infected intestine, and in normal peritoneum. To confirm an MC-
intrinsic role for ST2 in vivo, we performed peritoneal transfer of WT and St2−/− MC. 
In St2−/− hosts treated with IL-33 and in WT hosts subjected to thioglycollate peritonitis, WT MC 
displayed a clear survival advantage over coengraftedSt2−/− MC. IL-33 blockade specifically 
attenuated this survival advantage, confirming IL-33 as the relevant ST2 ligand mediating MC 
survival in vivo. Together, these data reveal a cell-intrinsic role for the IL-33/ST2 axis in the 
regulation of apoptosis in MC, identifying thereby a previously unappreciated pathway 
supporting expansion of the MC population with inflammation. 
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Article: 
Mast cells (MC) are tissue-resident effector cells that contribute both to innate and adaptive 
immunity (1). MC help defend against bacterial and helminthic infection (2, 3) and play a role in 
tissue remodeling (4, 5). MC can also contribute to a variety of allergic and nonallergic 
inflammatory diseases, such as anaphylaxis, atopic dermatitis, asthma, inflammatory arthritis, 
psoriasis, and multiple sclerosis (6, 7). Under many of these conditions, the number of MC in 
affected tissues increases by tenfold or more, amplifying the contribution of MC-derived 
mediators to ongoing inflammation (6⇓–8). Regulation of the MC population is poorly 
understood, and therapeutic intervention to limit MC accumulation potentially could attenuate 
injury associated with inflammatory diseases (9, 10). 
The survival of mature MC in tissues depends on signals from neighboring cells (11, 12). The 
single most important mediator in this process is stem cell factor (SCF), a master regulator of 
MC proliferation, differentiation, survival, and activation. Mice with genetic mutations affecting 
SCF or its receptor Kit have few or no MC in healthy or inflamed tissues, whereas activating 
mutations of Kit give rise to pathologic mastocytosis (13⇓–15). IL-3 is another well-recognized 
MC growth factor (16). SCF/Kit and IL-3 interface with several antiapoptotic pathways, up-
regulating the antiapoptotic protein B-cell lymphoma-2 (BCL-2) and downregulating the 
proapoptotic protein Bim (14, 17⇓–19). Aside from SCF/Kit and IL-3, other cytokines have been 
reported to support MC survival, but their effects appear to be restricted to specific MC subtypes. 
IL-4 promotes survival of intestinal MC via both BCL-2 and B-cell lymphoma-X large (BCLXL) 
but may suppress survival in human cord blood MC as well as murine bone marrow-derived MC 
(BMMC) (20⇓⇓–23). IL-10 can either promote or impair survival depending on the type of MC 
studied (21, 22). 
Recently, substantial attention has focused on the role of IL-33 in MC biology. A member of the 
IL-1 family, IL-33 is expressed primarily by stromal cells, such as epithelial cells, endothelial 
cells, and fibroblasts, as well as by certain hematopoietic cells, including MC themselves (24⇓–
26). IL-33 is an “alarmin” released upon cell necrosis and also can be secreted by live cells after 
mechanical stretching and via other incompletely defined mechanisms (27, 28). Its receptor ST2 
(also called IL-1 receptor-related protein 1) is highly expressed by MC. Acting via ST2, IL-33 
participates in MC activation in murine models of anaphylaxis and arthritis, serving both as a 
direct MC activator and as a factor that primes MC for enhanced cytokine release upon 
subsequent stimulation by IgE and IgG (29⇓⇓–32). IL-33 also prominently modulates the MC 
phenotype, promoting accumulation of MC protease 6 (the murine ortholog of human tryptase β) 
in vitro and in vivo (33). 
In cardiomyocytes and hepatocytes, IL-33 protects against apoptosis (34, 35), raising the 
possibility of an analogous effect in MC. Improved in vitro survival has been observed in human 
umbilical cord blood-derived MC exposed to IL-33 and in cultured murine MC under certain 
conditions, but this effect is incompletely characterized, and its relevance in vivo remains 
unknown (36, 37). In the present study, we show that IL-33 promotes the survival of both human 
and murine MC, mediated principally by up-regulation of the antiapoptotic factor BCLXL. In 
vivo, IL-33 and ST2 play a nonredundant role in promoting MC survival in peritoneum and 
potentially other sites. These data reveal a role for the IL-33/ST2 axis in the survival of tissue 
MC, particularly in the context of inflammation, raising the possibility that this axis could be 
targeted to limit the contribution of MC to chronic inflammatory diseases. 
Results 
IL-33 Sustains Human MC Survival via BCLXL. 
Human MC were cultured from human skin in serum-free medium containing SCF (38). Growth 
factor withdrawal is a standard model of apoptosis induction (39). Accordingly, MC (1 × 
105/mL) were treated with or without IL-33 (10 ng/mL) in the presence or absence of SCF for 3 
d. The percentage of apoptotic MC [Annexin V+ propidium iodide (PI)−] was measured using 
flow cytometry. IL-33 significantly inhibited MC apoptosis, reducing the fraction of cells 
undergoing apoptosis by a factor of three (Fig. 1A). To clarify whether this effect could reflect 
enhanced proliferation of surviving cells, we performed a carboxyfluorescein succinimidyl ester 
(CFSE) dilution assay. No difference in proliferation was observed after IL-33 stimulation, 
confirming that reduction of apoptosis was the sole basis for enhanced survival in IL-33–
stimulated human MC (Fig. 1B). 
 
Fig. 1. IL-33 promotes the survival of human skin-derived MC by up-regulating BCLXL gene expression. 
(A) Human skin-derived MC at 1 × 105/mL were treated with or without IL-33 (10 ng/mL) in the presence 
or absence of SCF for 3 d. MC apoptosis was assessed by flow cytometry. (B) Cell division was measured 
by CFSE dilution assay in live MC (Annexin V−PI−) with or without IL-33 in the absence of SCF for 3 d. 
Gray shading is unlabeled control. (C) MC at 1 × 105/mL were stimulated with IL-33 (10 ng/mL) for 1, 2, 
or 3 d in replicates. The relative gene expression ofBCLXL and BCL-2 was measured using real-time 
PCR. Data are representative of at least two donors and three independent experiments. (D) Twenty-four 
hours after siRNA transfection, MC were treated with or without IL-33 (10 ng/mL) in the presence or 
absence of SCF for 3 d. The fold increase in apoptosis was calculated by normalizing each group to its 
baseline in the presence of SCF. The data presented are combined from three independent experiments. 
*P < 0.05; **P < 0.01; NS, not significant. 
BCLXL and BCL-2 play central roles in the regulation of cell survival in human MC 
(11, 40, 41). To test the effect of IL-33 on BCLXL and BCL-2, we analyzed expression 
of BCLXL and BCL-2 using quantitative PCR after 1, 2, and 3 d of stimulation with IL-33. 
Interestingly, IL-33 increased the expression of BCLXL but notBCL-2 (Fig. 1C). To confirm the 
involvement of BCLXL, we used gene silencing. BCLXL or BCL-2 were each targeted with two 
different siRNA sequences. For both genes, the knockdown efficacy of siRNA #2 (∼90%) was 
more potent than that of siRNA #1 (∼60%) (Fig. S1A). Under SCF culture conditions, potent 
knockdown of either gene increased apoptosis by 1.4- to 1.7-fold (Fig. S1B) (16). The protective 
effect of IL-33 was almost abolished by silencing BCLXL, whereas BCL-2 knockdown had a 
minor impact (Fig. 1D). Taken together, these results indicate that IL-33 protects human MC 
from apoptosis primarily through expression of BCLXL. 
The IL-33 Receptor ST2 Is Required for the Prosurvival Effect of IL-33. 
ST2 is the only known receptor for IL-33. Recently, inconsistent experimental results 
in Il33−/− and St2−/− mice have raised the possibility that other receptor(s) might play a role in IL-
33 responses (42). To clarify whether the prosurvival effect of IL-33 on MC is mediated through 
ST2 and to assess whether murine models could be used to assess the in vivo importance of the 
IL-33/ST2 axis in MC survival, we generated murine BMMC from WT and St2−/− mice (43). 
Consistent with our human findings, IL-33 dose-dependently inhibited apoptosis and promoted 
the viability of BMMC subjected to cytokine deprivation (Fig. 2 A and B). This effect was 
completely abolished in St2−/− BMMC, confirming that ST2 is the only IL-33 receptor mediating 
the prosurvival function of IL-33 in these cells. As in human MC, the survival benefit of IL-33 
was mediated exclusively by reduced apoptosis, because, unlike SCF, IL-33 failed to promote 
cell division as assessed by CFSE dilution (Fig. 2C). Consistent with our human data, we found 
that IL-33 specifically enhanced expression of BCLXL but not BCL-2 (Fig. 2 D–F). In contrast, 
exposure to the alternate murine BMMC survival factor IL-3 was associated with up-regulation 
of BCL-2 instead of BCLXL, demonstrating that the IL-33/ST2 axis represents a distinct 
pathway of protection from apoptosis (Fig. 2 D–F). These results confirm the importance of 
BCLXL in attenuating MC apoptosis by IL-33 and establish an essential role for ST2 in this 
effect. 
 
Fig. 2. The prosurvival effect of IL-33 depends on the expression of its receptor ST2. (A) WT 
and St2−/− BMMC (1 × 106/mL) were treated with or without IL-33 at 1 or 10 ng/mL in the absence of 
SCF/IL-3. MC apoptosis was assessed by flow cytometry after 3 d. (B) Cell viability in parallel wells was 
measured using alamarBlue dye. (C) Cell proliferation was analyzed by CFSE dilution assay on day 5. 
(D) BMMC at 1 × 106/mL were stimulated with 10 ng/mL of IL-33 or IL-3 in the absence of SCF for 24 
h. Relative gene expression of Bclxl and Bcl-2 was analyzed by using real-time PCR. (E and F) The 
protein expression of BCLXL (E) and BCL-2 (F) was assessed using intracellular staining followed by 
flow cytometric analysis. Data are representative of at least two donors and two or three separate 
experiments. *P < 0.05; **P < 0.01; NS, not significant. 
IL-33 Promotes BMMC Survival in both a Direct and an Indirect Manner. 
IL-33 stimulation of MC induces the elaboration of numerous mediators (32, 37, 44, 45), raising 
the possibility that IL-33 might promote MC survival indirectly through the production of other 
factors. Therefore we used St2−/− BMMC to test the role of factors released by MC upon IL-33 
exposure. WT and St2−/− MC were cultured together in a Transwell system wherein these cell 
populations were separated by a 0.4-μm filter to permit free diffusion of soluble mediators but 
allow separate analysis of each cell type. In this shared environment, IL-33 attenuated apoptosis 
of WT MC to a significantly greater extent than St2−/− MC, confirming a direct ST2-mediated 
effect of IL-33 on MC survival (Fig. 3A). However, IL-33–stimulated WT BMMC partially 
rescued cocultured St2−/−MC, indicating the release of non–IL-33 factors that also can 
contribute to survival (Fig. 3A). Consistent with this result, supernatants from WT BMMC 
cultured with or without IL-33 partially attenuated apoptosis of St2−/− BMMC subjected to 
growth factor deprivation (Fig. 3B). This effect was unaccompanied by induction 
ofBclxl in St2−/− BMMC (Fig. 3C), demonstrating that promotion of survival via BCLXL in this 
context is a direct and specific result of ST2 engagement. 
 
Fig. 3. IL-33 promotes MC survival in a direct and an indirect manner. (A) WT and St2−/− BMMC were 
introduced into the top or bottom chamber of a Transwell system (pore size 0.4 μm; Costar Corp.), or vice 
versa. Cocultured cells were treated with IL-33 (10 ng/mL) for 3 d after deprivation of SCF/IL-3. MC 
apoptosis was assessed by flow cytometry. (B) IL-33–conditioned medium was collected from WT 
BMMC culture either with or without IL-33 treatment in the absence of SCF/IL-3 after 1, 2, and 3 d and 
was transferred into the parallel St2−/− BMMC culture without SCF/IL-3. The cell apoptosis 
in St2−/− BMMC was evaluated after 3 d. (C) IL-33–conditioned medium collected on day 2 was 
transferred to St2−/− BMMC culture. After 24 h, the gene expression ofBclxl was evaluated by using real-
time PCR. Data are representative of at least two independent experiments. *P < 0.05; **P < 0.01; NS, 
not significant. 
ST2 Deficiency Is Associated with Impaired MC Accumulation in Vivo. 
Compared with cultured MC, tissue-resident MC exhibit a diverse range of phenotypes and a 
much more complex set of local environments. To examine a role for IL-33/ST2 in vivo, we 
enumerated MC in tissues from WT and St2−/−mice in the waning phase of inflammation, when 
reduced SCF expression might relatively deprive an expanded MC population of growth factor 
support (46). We tested two models. K/BxN arthritis is an IgG-mediated immune complex 
arthritis that induces marked joint tissue inflammation within a few days of i.p. administration of 
arthritogenic serum. In this model, the number of MC in inflamed joint tissues more than doubles 
over the course of disease (47). Despite a somewhat milder course of arthritis in St2−/− mice, 
MC accumulation in actively inflamed joints at day 4 after the administration of K/BxN serum 
has been shown to be similar in WT and St2−/− animals (48), suggesting no significant 
difference in MC expansion during the initiation phase. We therefore examined synovial MC 
density at a point when the intensity of inflammation has begun to decline, day 10 after the 
administration of K/BxN serum. Consistent with our hypothesis, we found MC density to be 
reduced in both paw (Fig. S2) and ankle tissue (Fig. 4 A and B) in St2−/− animals. Next, we 
investigated intestinal helminth infection. After introduction of Trichinella spiralis by gavage, a 
robust intestinal accumulation of MC peaks at ∼14 d, declining progressively thereafter (49). 
Deficiency of ST2 does not affect intestinal worm burden, although these animals exhibit 
reduced intestinal Th2 responses and an enhanced larval burden in muscle (32, 48, 50). At 
analysis on day 21 after infection, the number of tissue MC was substantially lower 
in St2−/− mice than in control mice, suggesting that IL-33 has a role in the maintenance rather 
than the expansion of tissue MC populations (Fig. S3). 
 
Fig. 4. MC accumulation in inflamed joints is attenuated in St2−/−mice. K/BxN arthritis was induced by 
i.p. injection of arthritic serum. (A) On day 10, joints were removed and evaluated by toluidine blue. (B) 
The MC numbers in normal and arthritic ankles were quantified in three different areas per section under 
a light microscope. (Magnification: 200×.) Data are representative of three independent experiments. 
**P < 0.01. 
WT MC Display a Cell-Intrinsic Survival Advantage over St2−/− MC in Murine Peritoneum. 
Although consistent with our expectations, conclusions based on comparing WT 
with St2−/− mice are inherently limited. ST2 is broadly expressed, and differences in MC 
density inevitably will reflect the role of ST2 in the development, tissue localization, and effector 
activity of multiple lineages. Therefore we sought a more tractable model to test whether ST2 
confers a cell-intrinsic survival benefit on MC. 
Peritoneal MC are mature connective tissue MC easily identified by flow cytometry through the 
high expression of surface FcεRI and Kit (51, 52) (Fig. 5A). Interestingly, and in contrast to our 
findings in healthy gut and joint tissue, we observed that St2−/− mice exhibited relatively fewer 
peritoneal MC than WT animals (∼0.5% vs. ∼1.4% of CD45+ peritoneal leukocytes) (Fig. 5A). 
Recognizing that peritoneal lining cells express IL-33 (53), we elected to use the peritoneal 
environment to study the role of the IL-33/ST2 axis on MC survival in vivo. We adapted an 
established MC i.p. engraftment system (54), choosing to analyze transferred cells within 1 wk 
of engraftment to minimize potential effects of ST2 on engraftment efficiency and tissue 
localization. WT and St2−/− BMMC (1.5 × 106 cells each) were labeled with CFSE plus 
CellTracker Orange or with CFSE alone, respectively, and were transferred i.p. together 
into St2−/− recipients, thereby allowing us to compare survival and proliferation of these cells 
within the same environment. In preliminary studies, the number of recovered donor cells ranged 
from ∼0.9–1.6 × 105 after 3 d; the proportion of dye-labeled cells in total CD45+ cells ranged 
from 14 to 20%, whereas the proportion of endogenous recipient MC ranged from 1.7 to 2.1%. 
The recovered dye-labeled cells were confirmed to be Kit+, excluding the possibility that 
peritoneal scavengers phagocytizing fluorescent debris could have been misidentified as 
engrafted MC. Recombinant IL-33 (100 ng per mouse) then was administered i.p. once daily, 
followed by collection of peritoneal cells on day 6 to determine cell survival, apoptosis, and 
proliferation. On average, ∼65% of labeled cells remaining on day 6 were WT, and ∼35% 
were St2−/− (Fig. 5B; flow cytometry gating strategy is shown in Fig. S4). This effect did not 
represent an intrinsic growth or survival advantage of WT BMMC, as demonstrated by 
equivalent survival of WT and St2−/− BMMC in culture (Fig. S5; see also Fig. 2A). Consistent 
with our in vitro data, transferred St2−/− BMMC exhibited a slightly higher percentage of early 
apoptotic cells than WT MC (Fig. 5C) in the absence of any difference in proliferation as 
determined by CFSE dilution (Fig. 5D). Further, WT but not St2−/− BMMC exhibited enhanced 
expression of Bclxl but notBcl-2 (Fig. 5E). Thus, a direct and ST2-specific survival benefit 
associated with enhanced expression of BCLXL emerged clearly in this complex in vivo milieu. 
Notably, only 3–4% of transferred cells harvested on day 6 exhibited apoptosis, presumably 
because apoptotic cells are removed rapidly by host peritoneal cells through phagocytosis. 
 
Fig. 5. WT MC display a survival advantage over St2−/− MC in response to IL-33 in murine peritoneum. 
(A) Peritoneal cells were harvested by peritoneal lavage from WT andSt2−/− mice (n = 5). The proportions 
of resident MC (CD45+Kit+FcεRI+) in total leukocytes (CD45+) were analyzed using flow cytometry. (B) 
A 1:1 mixture (1.5 × 106 each) of WT and St2−/− BMMC labeled with CFSE plus CellTracker Orange and 
CFSE alone, respectively, or vice versa, was transferred into peritoneum in St2−/−mice on day 0. IL-33 
(100 ng per mouse) was administered i.p. every day for 6 d, and the survival of MC in peritoneum on day 
6 was analyzed by flow cytometry. Representative plots show WT and St2−/− MC populations; 
quantitative data reflect the proportion of remaining donor WT and St2−/− MC in each mouse. (C) The 
percentage of apoptotic cells (Annexin V+Live/Dead−) in each population. (D) Assessment of 
proliferation by CFSE fluorescence. (E) Bclxl and Bcl-2 mRNA levels in WT and St2−/− MC populations 
harvested from murine peritoneum on day 6 (samples analyzed individually from n = 5–6 mice). Data are 
representative of two independent experiments. *P < 0.05, **P < 0.01; NS, not significant. 
The IL-33/ST2 Axis Contributes to MC Survival in Peritonitis. 
  
To test whether ST2 expression conferred a survival advantage under conditions of 
inflammation, equal numbers of labeled WT and St2−/−BMMC were engrafted i.p. into WT 
animals with or without peritonitis induced by thioglycollate. The cells engrafted well in both 
normal and inflammatory conditions (0.76 ± 0.13 × 105, n = 2 and 1.70 ± 0.10 × 105, n= 5, 
recovered after 6 d from normal and inflamed peritoneum, respectively, in preliminary studies). 
Consistent with our earlier results, expression of ST2 favored survival as indicated by a decrease 
in the ratio of St2−/− to WT MC recovered, and this advantage was enhanced in the inflamed 
environment (Fig. 6A). Importantly, cytokine neutralization via a blocking anti–IL-33 antibody 
(32, 55) (Fig. S6) attenuated the survival advantage of WT over St2−/− BMMC (Fig. 6B), 
confirming involvement of IL-33 in the survival of MC in the inflamed peritoneum. In the 
absence of peritonitis, we identified no effect of anti–IL-33 blocking antibody on the St2−/−/WT 
cell ratio (Fig. S7). 
 
Fig. 6. The IL-33/ST2 axis contributes to MC survival in thioglycollate (TG)-induced peritonitis. (A) 
Peritonitis was initiated by i.p. injection of thioglycollate 1 d before cell transfer. A 1:1 mixture of WT 
and St2−/− BMMC labeled with CFSE plus CellTracker Orange and CFSE or of CD45.1 WT and 
CD45.2 St2−/− BMMC (2 × 106 each) labeled with CFSE was transferred to normal or inflamed 
peritoneum in WT mice. Surviving cells were harvested and analyzed using flow cytometry after 3 or 6 d. 
(B) IL-33 antibody (Nessy-1) or an isotype antibody was given to mice with peritonitis (40 μg per mouse, 
i.p., for 3 d). After 3 d, the ratio of surviving St2−/− to WT MC was assessed by flow cytometry. Data are 
representative of two to six independent experiments. *P < 0.05, **P < 0.01. 
Discussion 
Mast cells are found in most healthy vascularized tissues, and their numbers expand markedly 
under inflammatory conditions (56). Multiple lines of evidence show that mediators from 
surrounding cells are critical to the regulation of MC phenotype and survival, although many 
mechanistic details are lacking (57). The present findings demonstrate that IL-33, acting via its 
receptor ST2, represents an antiapoptotic signal for both murine and human MC and that the IL-
33/ST2 axis plays a previously unrecognized role to support MC survival in vivo. 
Mechanistically, we find that IL-33 drives expression of the antiapoptotic protein BCLXL and 
that BCLXL is the principal mediator of IL-33–mediated protection. This pathway only partially 
overlaps the pathway by which IL-33 supports the survival of other cell types. In rat 
cardiomyocytes, IL-33 abrogates hypoxia-induced apoptosis in association with elevation of a 
series of antiapoptotic molecules, including BCLXL, BCL-2, c-IAP, c-IAP2, XIAP, and 
survivin; this effect is specific to hypoxia and is not observed under conditions of normal oxygen 
tension (34). In murine hepatocytes, IL-33 suppresses apoptosis in Concanavalin A-induced 
hepatitis through up-regulation of BCL-2 and down-regulation of Bax (35). Thus, the pathways 
by which IL-33 prevents cell death vary with cell type and the conditions inducing apoptosis. 
In MC, BCL-2 and BCLXL can each promote survival, and inhibition of both essentially 
eliminates MC in vivo, confirming that they represent the antiapoptotic molecules of dominant 
physiological relevance for MC (58,59). Both BCL-2 and BCLXL strongly bind and inhibit 
active Bax, thereby preventing this apoptotic effector from damaging the mitochondrial outer 
membrane and precipitating cellular demise (41). Bax is known to play a preeminent role 
mediating apoptosis induced by growth factor deprivation (60). Our data reveal that either SCF 
or IL-3 (acting via BCL-2) or IL-33 (acting via BCLXL) can sustain MC populations exposed to 
this proapoptotic stress (18, 19, 58). Whether other causes of apoptosis, such as hypoxia, engage 
the same pathways remains to be determined. 
The survival signals that protect MC from apoptosis and thereby allow accumulation in tissues 
likely will vary with context and probably are complex. We find that WT MC survive better 
than St2−/− MC cotransferred into the peritoneum in the presence of exogenous IL-33 or under 
conditions of thioglycollate peritonitis. In some of these experiments, the recipients themselves 
were St2−/− mice, excluding graft rejection as the cause of this effect. In thioglycollate peritonitis, 
differential survival was attenuated by IL-33 blockade. No similar effect of IL-33 blockade 
emerged in the absence of induced inflammation, although we did observe a relative paucity of 
peritoneal MC in St2−/− mice compared with their WT counterparts, likely reflecting the 
inadequacy of our short-term engraftment system to model all facets of ST2-mediated MC 
persistence in the peritoneum. These findings confirm that, in the peritoneum, the IL-33/ST2 axis 
can play an important role in MC preservation, potentially because these free-floating cells have 
reduced access to surface-bound SCF. In contrast, in synovium and intestine, the MC population 
is numerically normal under healthy conditions and in early, but not later, inflammation. ST2 
plays multiple roles in these complex models, prohibiting firm conclusions about the role of 
ST2-mediated protection from apoptosis. Even if MC were the only cells lacking ST2, we still 
would be unable to disentangle differential apoptosis from effects of ST2 on MC development, 
distribution, or ST2-based interaction with neighboring cells. Despite this limitation, the results 
from arthritis and helminth infection remain strikingly concordant with our in vitro findings and 
in vivo peritoneal data, lending plausibility to the suggestion that the role of ST2 confirmed in 
our peritoneal transfer experiments may be operative more broadly, including in tissue MC. 
Beyond the direct antiapoptotic effect of ST2 ligation on MC, we show that IL-33 also can 
promote MC survival indirectly by triggering MC to produce soluble factors that contribute to 
their own survival. MC exposed to IL-33 produce numerous mediators (6, 8, 32, 37, 44, 45), and 
the cytokine or combination of cytokines that promote survival of bystander St2−/− MC in our 
system remains to be determined. Interestingly, we find these indirect signals operate 
independently of Bclxl up-regulation, highlighting the relative specificity of this pathway for IL-
33/ST2. 
Our studies used skin-derived human MC, murine BMMC, and murine peritoneal, synovial, and 
intestinal MC. The consistency of our findings suggests that the prosurvival effect of IL-33/ST2 
in MC may be broadly conserved. Further investigation is required to confirm the effect of IL-
33/ST2 on specific types of MC and in other tissues and disease states. Given the diversity of 
MC phenotypes and inflammatory tissue settings, it is likely that IL-33 will play a more 
important role for MC survival in some contexts than in others. 
Our findings raise the interesting possibility that antagonism of IL-33 or ST2 could selectively 
attenuate MC accumulation in chronically inflamed tissues. Whether such disruption of MC 
expansion will help the host may vary with disease context. MC can produce a range of lipids, 
cytokines, and proteases, depending on the stimulus and the MC’s developmental phenotype. At 
the start of an inflammatory process, tissue MC populations usually are relatively sparse, serving 
primarily as sentinels rather than as major effectors of innate immunity. As their numbers expand 
with inflammation, the role MC play likely evolves (7). In chronic inflammation, MC could 
continue to “feed the fire” via ongoing mediator release, antigen presentation, or other 
mechanisms. Alternately, MC could help suppress disease, for instance by protease-mediated 
elimination of proinflammatory mediators, by facilitating tissue remodeling, or by promoting 
tolerance (61⇓⇓–64). The effect of attenuating MC survival by blocking the IL-33/ST2 axis will 
be important to consider when evaluating IL-33 and ST2 as potential therapeutic targets. 
Materials and Methods 
Human skin MC were cultured as described previously (38). Mouse BMMC were developed 
from mouse bone marrow as described previously (32). Real-time PCR, siRNA knockdown, and 
flow cytometry were performed as indicated in SI Materials and Methods. Arthritis was induced 
by the i.p. injection of K/BxN serum as previously described (32). MC quantification was 
performed blindly on paraffin-embedded 4-µm sections stained with toluidine blue using 
established methods. Peritonitis was initiated by instillation of 1 mL of sterile aged 3% (wt/vol) 
thioglycollate broth i.p. 1 d before cell transfer. WT and St2−/− BMMC were transferred at a 1:1 
ratio into peritoneum. Some groups were injected with isotype antibody or anti–IL-33 (Nessy-1; 
Enzo Life Sciences) (40 µg per mouse, i.p. once daily). Animal experiments were approved by 
the Institutional Animal Care and Use Committee of the Dana-Farber Cancer Institute (Animal 
Welfare Assurance Number: A3023-01). All efforts were made to minimize the suffering of 
animals used in this research. Statistical analysis was performed using Student t test, and data 
were analyzed using GraphPad Prism software version 4. Results are presented as the mean ± 
SEM. P values less than 0.05 were considered significant. 
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